Guido Fallani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Guido Fallani has a total of 173 co-authors. Here are the top co-authors by number of shared publications:
- Matteo Ravaioli
Department of Medical and Surgical Sciences University of Bologna Bologna Italy
18 shared publications - Antonio Siniscalchi
Postoperative and Abdominal Organ Transplant Intensive Care Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
10 shared publications - Lorenzo Maroni
IRCCS Azienda Ospedaliero‐Universitaria di Bologna Bologna Italy
10 shared publications Matteo Cescon
Hepato-biliary and Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di. Bologna, Bologna, Italy
10 shared publications- Giuliana Germinario
IRCCS Azienda Ospedaliero‐Universitaria di Bologna Bologna Italy
9 shared publications - Matteo Serenari
Hepato-biliary Surgery and Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
8 shared publications
Latest Publications
- 12 October 2026
- Published by SAGE Publications in Journal of Laparoendoscopic & Advanced Surgical Techniques
Tumor Biology and Surgical Margin Patterns in Colorectal Liver Metastases: Association Between KRAS/BRAF Status and Type of Resection Margin—BRAF-KRAS LiverMet Collaborative Group
Background: Surgical strategies for colorectal liver metastases (CRLM) have progressively evolved toward parenchyma-sparing approaches, increasing the relevance of understanding the relationship between tumor biology and resection margin patterns. In parallel, KRAS and BRAF mutations have emerged as key determinants of tumor behavior in CRLM. The interaction between mutational status and surgical margin type, however, remains insufficiently characterized. Methods: This multicenter retrospective study included patients undergoing curative-intent liver resection for CRLM between 2016 and 2021 across 17 international HPB centers. Clinicopathological variables were compared according to mutational status and margin type. Results: Among 1078 eligible patients, KRAS-mutated patients more frequently presented synchronous metastases, nodal involvement, and administration of perioperative chemotherapy compared with wild-type patients. Higher tumor burden was associated with both R1 parenchymal (R1P) and R1 vascular (R1V) resections. Within KRAS-mutated patients, synchronous disease and bilobar involvement were more frequently associated with R1P resections. Conclusions: KRAS/BRAF mutational status is associated with distinct clinicopathological patterns in patients undergoing liver resection for CRLM. Higher tumor burden and biologically aggressive disease features are more frequently associated with R1P and R1V resections, particularly among KRAS-mutated tumors.
- 12 October 2026
- Published by SAGE Publications in Journal of Laparoendoscopic & Advanced Surgical Techniques
Tumor Biology and Surgical Margin Patterns in Colorectal Liver Metastases: Association Between KRAS/BRAF Status and Type of Resection Margin—BRAF-KRAS LiverMet Collaborative Group
Background: Surgical strategies for colorectal liver metastases (CRLM) have progressively evolved toward parenchyma-sparing approaches, increasing the relevance of understanding the relationship between tumor biology and resection margin patterns. In parallel, KRAS and BRAF mutations have emerged as key determinants of tumor behavior in CRLM. The interaction between mutational status and surgical margin type, however, remains insufficiently characterized. Methods: This multicenter retrospective study included patients undergoing curative-intent liver resection for CRLM between 2016 and 2021 across 17 international HPB centers. Clinicopathological variables were compared according to mutational status and margin type. Results: Among 1078 eligible patients, KRAS-mutated patients more frequently presented synchronous metastases, nodal involvement, and administration of perioperative chemotherapy compared with wild-type patients. Higher tumor burden was associated with both R1 parenchymal (R1P) and R1 vascular (R1V) resections. Within KRAS-mutated patients, synchronous disease and bilobar involvement were more frequently associated with R1P resections. Conclusions: KRAS/BRAF mutational status is associated with distinct clinicopathological patterns in patients undergoing liver resection for CRLM. Higher tumor burden and biologically aggressive disease features are more frequently associated with R1P and R1V resections, particularly among KRAS-mutated tumors.
- Open Access
- 9 July 2026
- Published by Elsevier in Journal of Liver Transplantation
- Vol. 23
End-Ischemic HOPE Rescue of Declined Liver Grafts After Prolonged Static Cold Storage: Three Cases With 6-Year Graft Survival
- 9 July 2026
- Published by Elsevier in Journal of Liver Transplantation
- Vol. 23
Open AccessEnd-Ischemic HOPE Rescue of Declined Liver Grafts After Prolonged Static Cold Storage: Three Cases With 6-Year Graft Survival
- Open Access
- 28 April 2026
- Published by Wiley in Artificial Organs
- Vol. 50 (7) , 1027-1036
Pushing the Limit for Marginal Grafts in the Era of Machine Perfusion: A Tale of HOPE From a Leading Italian Institution
Background: The advent of machine perfusion (MP) has significantly improved post‐liver transplantation (post‐LT) outcomes, potentially enabling the use of increasingly marginal grafts and expanding the organ donor pool. Methods: We present a retrospective cohort study of consecutive adult patients who underwent LT between 2018 and 2023 at a leading Italian institution. The objective was to evaluate outcomes following the use of hypothermic oxygenated perfusion (HOPE) in high‐risk grafts. Results: A total of 507 patients were included in the final analysis, of whom 420 (83%) received extended criteria donor (ECD) grafts. Among ECD grafts, 62 (15%) were from donation after circulatory death (DCD) donors, and 64 (15%) were previously discarded by other centers. HOPE was applied in 248 (49%) cases. Recipients in the HOPE group experienced significantly lower rates of early allograft dysfunction (EAD) (20% vs. 32%, p = 0.007), primary nonfunction (2% vs. 7%, p = 0.017), and severe postoperative complications (Clavien–Dindo grade ≥ 3b) (19% vs. 28%, p = 0.026). Notably, marginal grafts treated with HOPE achieved survival outcomes comparable to those of standard risk. Conclusions: HOPE is associated with improved outcomes in LT using ECD grafts and can enable the safe use of higher‐risk organs with acceptable results when performed in experienced centers.
- 28 April 2026
- Published by Wiley in Artificial Organs
- Vol. 50 (7) , 1027-1036
Open AccessPushing the Limit for Marginal Grafts in the Era of Machine Perfusion: A Tale of HOPE From a Leading Italian Institution
Background: The advent of machine perfusion (MP) has significantly improved post‐liver transplantation (post‐LT) outcomes, potentially enabling the use of increasingly marginal grafts and expanding the organ donor pool. Methods: We present a retrospective cohort study of consecutive adult patients who underwent LT between 2018 and 2023 at a leading Italian institution. The objective was to evaluate outcomes following the use of hypothermic oxygenated perfusion (HOPE) in high‐risk grafts. Results: A total of 507 patients were included in the final analysis, of whom 420 (83%) received extended criteria donor (ECD) grafts. Among ECD grafts, 62 (15%) were from donation after circulatory death (DCD) donors, and 64 (15%) were previously discarded by other centers. HOPE was applied in 248 (49%) cases. Recipients in the HOPE group experienced significantly lower rates of early allograft dysfunction (EAD) (20% vs. 32%, p = 0.007), primary nonfunction (2% vs. 7%, p = 0.017), and severe postoperative complications (Clavien–Dindo grade ≥ 3b) (19% vs. 28%, p = 0.026). Notably, marginal grafts treated with HOPE achieved survival outcomes comparable to those of standard risk. Conclusions: HOPE is associated with improved outcomes in LT using ECD grafts and can enable the safe use of higher‐risk organs with acceptable results when performed in experienced centers.
- Open Access
- 10 March 2026
- Published by Springer Nature in Updates in Surgery
- Vol. 78 (4) , 1-10
A journey from marginality to routine and beyond: single center experience with DCD utilization for liver transplantation in Italy
Donation after cardiovascular determination of death (DCD) has expanded the liver donor pool but remains limited by concerns over prolonged donor warm ischemia and inferior outcomes, particularly in countries such as Italy where legally mandated asystolic periods increase donor risk. This study evaluates trends in DCD liver transplantation at a high-volume Italian center, to assess whether accumulated experience and advanced reconditioning strategies influenced outcomes over time. We retrospectively analyzed adult DCD liver transplants performed between 2016 and 2023. Donor characteristics, recipient risk profiles, perfusion strategies, ischemia times, and post-transplant outcomes were compared between an early (2016–2021) and a late (2022–2023) period. Temporal trends were evaluated using linear regression. Seventy-five DCD liver transplants were included. Later-period recipients had more advanced liver disease (39.1% vs. 17.2% Child-Pugh C, p = 0.045) and higher P-SOFT and LTRS risk scores. Moreover, later-period donors were older (median 72 vs. 62 years, p = 0.022), and exhibited higher DRI and ET-DRI scores. Concurrently, HOPE duration increased, and total ischemia time decreased linearly with program maturation. Despite the progressive rise in donor and recipient risk, rates of early allograft dysfunction, biliary complications, retransplantations, and graft and patient survival remained unchanged between periods. In a high-risk regulatory setting, DCD liver transplantation outcomes remained stable despite increasing donor and recipient complexity. Program maturation, ischemia minimization, and prolonged hypothermic oxygenated perfusion appear to effectively mitigate DCD-associated risk, supporting broader and safer utilization of DCD liver grafts even in challenging clinical environments.
- 10 March 2026
- Published by Springer Nature in Updates in Surgery
- Vol. 78 (4) , 1-10
Open AccessA journey from marginality to routine and beyond: single center experience with DCD utilization for liver transplantation in Italy
Donation after cardiovascular determination of death (DCD) has expanded the liver donor pool but remains limited by concerns over prolonged donor warm ischemia and inferior outcomes, particularly in countries such as Italy where legally mandated asystolic periods increase donor risk. This study evaluates trends in DCD liver transplantation at a high-volume Italian center, to assess whether accumulated experience and advanced reconditioning strategies influenced outcomes over time. We retrospectively analyzed adult DCD liver transplants performed between 2016 and 2023. Donor characteristics, recipient risk profiles, perfusion strategies, ischemia times, and post-transplant outcomes were compared between an early (2016–2021) and a late (2022–2023) period. Temporal trends were evaluated using linear regression. Seventy-five DCD liver transplants were included. Later-period recipients had more advanced liver disease (39.1% vs. 17.2% Child-Pugh C, p = 0.045) and higher P-SOFT and LTRS risk scores. Moreover, later-period donors were older (median 72 vs. 62 years, p = 0.022), and exhibited higher DRI and ET-DRI scores. Concurrently, HOPE duration increased, and total ischemia time decreased linearly with program maturation. Despite the progressive rise in donor and recipient risk, rates of early allograft dysfunction, biliary complications, retransplantations, and graft and patient survival remained unchanged between periods. In a high-risk regulatory setting, DCD liver transplantation outcomes remained stable despite increasing donor and recipient complexity. Program maturation, ischemia minimization, and prolonged hypothermic oxygenated perfusion appear to effectively mitigate DCD-associated risk, supporting broader and safer utilization of DCD liver grafts even in challenging clinical environments.
- Open Access
- 21 January 2026
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 72 (10) , e321-e324
Inferior Vena Cava Resection Using Modified Veno-Venous Bypass With Renal Vein Drainage: Case Report Adapted From Liver Transplant Practice
We describe an innovative application of a modified three-arm veno-venous bypass (VVB) in the management of a complex case of recurrent renal cell carcinoma (RCC) invading the inferior vena cava (IVC) and left renal vein confluence. The patient, with a solitary kidney following right nephrectomy, underwent radical tumor resection and IVC reconstruction. To preserve renal function and minimize ischemic injury, we employed an extracorporeal circuit traditionally used in liver transplantation, adapting it to include an additional cannula in the left renal vein. This configuration allowed continuous renal venous drainage during IVC clamping, limiting kidney warm ischemia to only 14 minutes. The extracorporeal circuit included jugular and femoral venous drainage limbs connected to a centrifugal pump and a third limb providing direct renal outflow, effectively maintaining hemodynamic stability and renal perfusion. Postoperative recovery was uneventful, with transient minimal creatinine elevation and no acute kidney injury. This case demonstrates the versatility of extracorporeal venous bypass circuits in complex onco-vascular surgery and highlights the potential for broader applications of organ support technologies in preserving organ function during major vascular reconstruction. The proposed configuration represents a valuable adjunct in surgeries involving solitary kidneys and prolonged caval occlusion, bridging concepts from transplant and extracorporeal support domains.
- 21 January 2026
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 72 (10) , e321-e324
Open AccessInferior Vena Cava Resection Using Modified Veno-Venous Bypass With Renal Vein Drainage: Case Report Adapted From Liver Transplant Practice
We describe an innovative application of a modified three-arm veno-venous bypass (VVB) in the management of a complex case of recurrent renal cell carcinoma (RCC) invading the inferior vena cava (IVC) and left renal vein confluence. The patient, with a solitary kidney following right nephrectomy, underwent radical tumor resection and IVC reconstruction. To preserve renal function and minimize ischemic injury, we employed an extracorporeal circuit traditionally used in liver transplantation, adapting it to include an additional cannula in the left renal vein. This configuration allowed continuous renal venous drainage during IVC clamping, limiting kidney warm ischemia to only 14 minutes. The extracorporeal circuit included jugular and femoral venous drainage limbs connected to a centrifugal pump and a third limb providing direct renal outflow, effectively maintaining hemodynamic stability and renal perfusion. Postoperative recovery was uneventful, with transient minimal creatinine elevation and no acute kidney injury. This case demonstrates the versatility of extracorporeal venous bypass circuits in complex onco-vascular surgery and highlights the potential for broader applications of organ support technologies in preserving organ function during major vascular reconstruction. The proposed configuration represents a valuable adjunct in surgeries involving solitary kidneys and prolonged caval occlusion, bridging concepts from transplant and extracorporeal support domains.
- Open Access
Liver Transplantation for Colorectal Metastases: Impact of a Standardised Protocol for Patient Selection on Transplant Outcomes
Background: Colorectal liver metastases (CRLM) occur in up to 50% of colorectal cancer with a significant impact on patient survival, of whom only 20–30% will be considered suitable for surgical treatment. Despite the progress in systemic therapies, palliative chemotherapy alone results in a 5-year overall survival (OS) < 10%. Recently, liver transplantation (LT) has been reconsidered as an option and demonstrates improved survival in highly selected patients. This study assessed the impact of implementing a standardised patient selection protocol (LITORALE) on post-transplant outcomes for unresectable CRLM (uCRLM) at a high-volume single centre. Methods: This is a prospective observational study including all consecutive patients transplanted for uCRLM at our institution between July 2015 and September 2024. This prospective observational study evaluated the impact of the LITORALE protocol on post-transplant outcomes in uCRLM patients at a single centre. Patients who underwent LT between July 2015 and September 2024 were grouped into pre-LITORALE (2015–2021) and LITORALE (post-2021) cohorts. Recipient profiles, transplant variables, and post-transplant outcomes were compared. Results: Twenty-one patients were included (eight pre-LITORALE, thirteen LITORALE). The LITORALE group had a lower median number of lesions (4 vs. 17.5, p = 0.004), a smaller major lesion size (3 cm vs. 5.5 cm, p = 0.082), and a significantly lower tumour burden score (6.32 vs. 18.02, p = 0.002). Similar to recent major clinical trials, one- and three-years OS were 100% and 83%, respectively, after protocol introduction; recurrence patterns were significantly different, with reduced multi-site recurrences (7.7% vs. 50%, p = 0.048) and a higher incidence of lung-only recurrences in the LITORALE group (50% vs. 0%, p = 0.033). Conclusions: The introduction of the LITORALE protocol significantly influenced patient selection and recurrence patterns in LT for uCRLM. Although the limited number of patients and the short study timespan highlight the need for future validation, these preliminary results support the adoption of structured, multidisciplinary criteria to optimise oncologic outcomes.
Open AccessLiver Transplantation for Colorectal Metastases: Impact of a Standardised Protocol for Patient Selection on Transplant Outcomes
Background: Colorectal liver metastases (CRLM) occur in up to 50% of colorectal cancer with a significant impact on patient survival, of whom only 20–30% will be considered suitable for surgical treatment. Despite the progress in systemic therapies, palliative chemotherapy alone results in a 5-year overall survival (OS) < 10%. Recently, liver transplantation (LT) has been reconsidered as an option and demonstrates improved survival in highly selected patients. This study assessed the impact of implementing a standardised patient selection protocol (LITORALE) on post-transplant outcomes for unresectable CRLM (uCRLM) at a high-volume single centre. Methods: This is a prospective observational study including all consecutive patients transplanted for uCRLM at our institution between July 2015 and September 2024. This prospective observational study evaluated the impact of the LITORALE protocol on post-transplant outcomes in uCRLM patients at a single centre. Patients who underwent LT between July 2015 and September 2024 were grouped into pre-LITORALE (2015–2021) and LITORALE (post-2021) cohorts. Recipient profiles, transplant variables, and post-transplant outcomes were compared. Results: Twenty-one patients were included (eight pre-LITORALE, thirteen LITORALE). The LITORALE group had a lower median number of lesions (4 vs. 17.5, p = 0.004), a smaller major lesion size (3 cm vs. 5.5 cm, p = 0.082), and a significantly lower tumour burden score (6.32 vs. 18.02, p = 0.002). Similar to recent major clinical trials, one- and three-years OS were 100% and 83%, respectively, after protocol introduction; recurrence patterns were significantly different, with reduced multi-site recurrences (7.7% vs. 50%, p = 0.048) and a higher incidence of lung-only recurrences in the LITORALE group (50% vs. 0%, p = 0.033). Conclusions: The introduction of the LITORALE protocol significantly influenced patient selection and recurrence patterns in LT for uCRLM. Although the limited number of patients and the short study timespan highlight the need for future validation, these preliminary results support the adoption of structured, multidisciplinary criteria to optimise oncologic outcomes.
- Open Access
- 28 April 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (5) , e70166
Hypothermic Oxygenated Perfusion in Extended Criteria Donor Kidney Transplantation—A Randomized Clinical Trial
Background: The role of machine perfusion after kidney transplantation (KT) in extended criteria donors (ECD) is unclear, and the current evidence in the literature remains controversial.Methods: We present an open‐label single center randomized trial where 109 patients undergoing KT with ECD grafts between January 2019 and December 2022 were randomized to receive kidneys treated with either hypothermic oxygenated perfusion (HOPE, n = 54) or static cold storage (SCS, n = 55) alone. The primary endpoint was the incidence of delayed graft function (DGF). The secondary endpoints included postoperative complications and graft function and survival in the first year after KT.Results: The trial failed to meet its primary endpoint. DGF developed in 31 (57%) and 37 (67%) patients in the HOPE and SCS groups, respectively (p = 0.3). Posthoc analysis showed that HOPE was associated with a lower risk for DGF for grafts from donors aged 60 years or older (OR 0.32, 95% CI 0.12–0.87, p = 0.026) and in patients undergoing dual KTs (OR 0.22, 95% CI 0.06–0.87, p = 0.031).Conclusions: HOPE does not reduce the rate of DGF after KT in ECD donors. However, HOPE appears to be associated with better outcomes in the case of older donors and dual KTs.
- 28 April 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (5) , e70166
Open AccessHypothermic Oxygenated Perfusion in Extended Criteria Donor Kidney Transplantation—A Randomized Clinical Trial
Background: The role of machine perfusion after kidney transplantation (KT) in extended criteria donors (ECD) is unclear, and the current evidence in the literature remains controversial.Methods: We present an open‐label single center randomized trial where 109 patients undergoing KT with ECD grafts between January 2019 and December 2022 were randomized to receive kidneys treated with either hypothermic oxygenated perfusion (HOPE, n = 54) or static cold storage (SCS, n = 55) alone. The primary endpoint was the incidence of delayed graft function (DGF). The secondary endpoints included postoperative complications and graft function and survival in the first year after KT.Results: The trial failed to meet its primary endpoint. DGF developed in 31 (57%) and 37 (67%) patients in the HOPE and SCS groups, respectively (p = 0.3). Posthoc analysis showed that HOPE was associated with a lower risk for DGF for grafts from donors aged 60 years or older (OR 0.32, 95% CI 0.12–0.87, p = 0.026) and in patients undergoing dual KTs (OR 0.22, 95% CI 0.06–0.87, p = 0.031).Conclusions: HOPE does not reduce the rate of DGF after KT in ECD donors. However, HOPE appears to be associated with better outcomes in the case of older donors and dual KTs.
- 24 March 2023
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 69 (9) , e411-e414
VA-ECMO Cardiac Support During Liver Transplant: A Case Report
Extracorporeal membrane oxygenation (ECMO) is a rescue therapy for cardiovascular collapse during and after liver transplantation (LT). According to the most recent guidelines, patients with severe cardiomyopathy are excluded from LT because of high-mortality risk during surgery. Intraoperative ECMO support could give these patients the opportunity to undergo LT by reducing the risk of heart failure and reperfusion syndrome. In this case report, we present a case of veno-arterial ECMO (VA-ECMO) support started before LT surgery in a patient with severe pulmonary hypertension, mitral valve steno-insufficiency, and right heart dysfunction. The presence of severe heart disease would have contraindicated LT, but simultaneous liver cirrhosis contraindicated mitral valve surgery, leaving the patient locked in a “Catch-22” state. The best solution was to perform LT with VA-ECMO support before, during, and after the surgery to reduce cardiac load and possible heart failure. LT was performed with good hemodynamic stability and the patient was successfully weaned from ECMO a few hours after surgery. At the 6 month follow-up, normal liver and kidney functions were recorded as well as an overall improvement of heart function; the patient successfully underwent mitral valve replacement and tricuspid annuloplasty 10 months after transplant and is now in good condition.
- 24 March 2023
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 69 (9) , e411-e414
VA-ECMO Cardiac Support During Liver Transplant: A Case Report
Extracorporeal membrane oxygenation (ECMO) is a rescue therapy for cardiovascular collapse during and after liver transplantation (LT). According to the most recent guidelines, patients with severe cardiomyopathy are excluded from LT because of high-mortality risk during surgery. Intraoperative ECMO support could give these patients the opportunity to undergo LT by reducing the risk of heart failure and reperfusion syndrome. In this case report, we present a case of veno-arterial ECMO (VA-ECMO) support started before LT surgery in a patient with severe pulmonary hypertension, mitral valve steno-insufficiency, and right heart dysfunction. The presence of severe heart disease would have contraindicated LT, but simultaneous liver cirrhosis contraindicated mitral valve surgery, leaving the patient locked in a “Catch-22” state. The best solution was to perform LT with VA-ECMO support before, during, and after the surgery to reduce cardiac load and possible heart failure. LT was performed with good hemodynamic stability and the patient was successfully weaned from ECMO a few hours after surgery. At the 6 month follow-up, normal liver and kidney functions were recorded as well as an overall improvement of heart function; the patient successfully underwent mitral valve replacement and tricuspid annuloplasty 10 months after transplant and is now in good condition.
- Open Access
- 3 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (3) , 1239
Planned Extracorporeal Life Support Employment during Liver Transplantation: The Potential of ECMO and CRRT as Preventive Therapies—Case Reports and Literature Review
Liver Transplantation (LT) has become the gold standard treatment for End-Stage Liver Disease (ESLD). One of the main strategies to manage life-threatening complications, such as cardio-respiratory failure, is Extracorporeal Membrane Oxygenation (ECMO) in the peri-transplantation period, with different configurations of the technique and in combination with other extracorporeal care devices such as Continuous Renal Replacement Therapy (CRRT). This retrospective study includes three clinical cases of planned ECMO support strategies in LT and evaluates their application compared with current literature exploring PubMed/Medline. The three LT supported with ECMO and CRRT were performed at IRCCS Polyclinic S. Orsola-Malpighi, Bologna. All three cases of patients with compromised organ function analysed produced positive outcomes. The planned use of ECMO and CRRT support in peri-transplantation has allowed the patients to overcome contraindications and successfully undergo LT. In recent years, only a few reports have documented successful LT outcomes performed with intraoperative ECMO in critically ESLD patients. However, the management of LT with ECMO and/or CRRT assistance is an emerging challenge, with the need for more published evidence on this topic to guide treatment choices in patients with severe, acute and reversible respiratory and cardiovascular failure after LT.
- 3 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (3) , 1239
Open AccessPlanned Extracorporeal Life Support Employment during Liver Transplantation: The Potential of ECMO and CRRT as Preventive Therapies—Case Reports and Literature Review
Liver Transplantation (LT) has become the gold standard treatment for End-Stage Liver Disease (ESLD). One of the main strategies to manage life-threatening complications, such as cardio-respiratory failure, is Extracorporeal Membrane Oxygenation (ECMO) in the peri-transplantation period, with different configurations of the technique and in combination with other extracorporeal care devices such as Continuous Renal Replacement Therapy (CRRT). This retrospective study includes three clinical cases of planned ECMO support strategies in LT and evaluates their application compared with current literature exploring PubMed/Medline. The three LT supported with ECMO and CRRT were performed at IRCCS Polyclinic S. Orsola-Malpighi, Bologna. All three cases of patients with compromised organ function analysed produced positive outcomes. The planned use of ECMO and CRRT support in peri-transplantation has allowed the patients to overcome contraindications and successfully undergo LT. In recent years, only a few reports have documented successful LT outcomes performed with intraoperative ECMO in critically ESLD patients. However, the management of LT with ECMO and/or CRRT assistance is an emerging challenge, with the need for more published evidence on this topic to guide treatment choices in patients with severe, acute and reversible respiratory and cardiovascular failure after LT.
- 1 March 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 76 (3) , 619-627
Impact of MELD 30-allocation policy on liver transplant outcomes in Italy
- 1 March 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 76 (3) , 619-627
Impact of MELD 30-allocation policy on liver transplant outcomes in Italy